PMID: 8603459Jan 1, 1996Paper

Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors

Cancer Chemotherapy and Pharmacology
S A van AckerA Bast

Abstract

In laboratory animals, histology is most commonly used to study doxorubicin-induced cardiotoxicity. However, for monitoring during treatment, large numbers of animals are needed. Recently we developed a new method to measure ECG values in freely moving mice by telemetry. With this model we investigated the effect of chronic doxorubicin administration on the ECG of freely moving BALB/c mice and the efficacy of ICRF-187 as a protective agent. The ST interval significantly widened from 15.0 +/- 1.5 to 56.8 +/- 11.8 ms in week 10 (7 weekly doses of 4 mg/kg doxorubicin given i.v. plus 3 weeks of observation). The ECG of the control animals did not change during the entire study. After sacrifice the hearts of doxorubicin-treated animals were enlarged and the atria were hypertrophic. As this schedule exerted more toxicity than needed to investigate protective agents, the protection of ICRF-187 was determined using a dose schedule with lower general toxicity (6 weekly doses of 4 mg/kg doxorubicin given i.v. plus 2 weeks of observation). On this schedule, the animals' hearts appeared normal after sacrifice and ICRF-187 (50 mg/kg given i.p. 1 h before doxorubicin) provided almost full protection. These data were confirmed by histology. T...Continue Reading

Citations

Mar 23, 2006·The American Journal of Chinese Medicine·Jyh-Sheng YouYing-Shiung Lee
Oct 12, 2007·The Journal of Pharmacology and Experimental Therapeutics·Kyoung-Han KimPeter H Backx
Dec 20, 2013·Assay and Drug Development Technologies·Cheng-Chen HuangKarl P Peterson
Feb 9, 2019·Naunyn-Schmiedeberg's Archives of Pharmacology·Nermin T El-SaidRagia A Taha
Sep 8, 2007·Toxicological Sciences : an Official Journal of the Society of Toxicology·Cheng-Chen HuangJohn Yu
Jun 5, 2014·Psychopharmacology·R SeigersS B Schagen
Dec 18, 2013·Cardiovascular Toxicology·Amir Abbas FarshidHossein Alavi
Nov 29, 2016·Fundamental & Clinical Pharmacology·Hui-Lin WangJian-Ping Gao
Mar 12, 2019·Canadian Journal of Physiology and Pharmacology·Nourelhuda A MohammedDoaa M Abdullah
Jan 12, 2000·Journal of Cardiovascular Pharmacology·R CirilloS Manzini
Mar 21, 2012·Fundamental & Clinical Pharmacology·Sergey KharinDmitry Shmakov
Mar 2, 2011·Journal of Pharmacological Sciences·Mari TomonariHitoshi Kurose
Oct 26, 2013·European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes·O M DisliH Parlakpinar
Oct 22, 2016·Advanced Pharmaceutical Bulletin·Nasser RazmaraiiYadollah Azarmi
Sep 7, 2019·Proceedings of the National Academy of Sciences of the United States of America·Jie LiPaul M Hwang
May 2, 2009·Toxicological Sciences : an Official Journal of the Society of Toxicology·Mehdi S HazariAimen K Farraj
Dec 24, 2005·Phytotherapy Research : PTR·Jyh-Sheng YouYing-Ling Chang
May 17, 2014·Journal of Applied Physiology·A Navarrete-Opazo, G S Mitchell
May 5, 2018·Amino Acids·Xingjuan ShiXiao-Yan Wen
May 15, 2003·Physiological Genomics·Klaas Kramer, Lewis B Kinter
Nov 21, 2020·Journal of cardiology·Toshio KinoshitaTakanori Ikeda
Feb 4, 2021·Animal Models and Experimental Medicine·Hailey HousonVibhudutta Awasthi
Jun 23, 2001·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·M M Sayed-AhmedM Calvani
Jan 13, 2001·Chemico-biological Interactions·G L Forrest, B Gonzalez
Feb 28, 2003·Chemico-biological Interactions·Gertjan J M den HartogAalt Bast
Jun 5, 2021·Nutrition and Cancer·Mahboobeh Ghasemzadeh RahbardarHossein Hosseinzadeh
Jan 23, 2004·Toxicology and Applied Pharmacology·Gertjan J M den HartogAalt Bast
Mar 3, 2007·Progress in Cardiovascular Diseases·Genzou Takemura, Hisayoshi Fujiwara
Nov 9, 2007·Toxicology·Roohollah Babaei KelishomiAhmad Reza Dehpour

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
F A van AckerWim J F van der Vijgh
Archives Internationales De Pharmacodynamie Et De Thérapie
G PerlettiF Piccinini
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
S A van AckerWim J F van der Vijgh
© 2021 Meta ULC. All rights reserved